Last reviewed · How we verify
Cyclophosphamide, Methotrexate, 5 FU
Cyclophosphamide is an alkylating agent that interferes with DNA replication, Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, and 5 FU is a thymidylate synthase inhibitor.
Cyclophosphamide is an alkylating agent that interferes with DNA replication, Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, and 5 FU is a thymidylate synthase inhibitor. Used for Breast cancer, Lymphoma.
At a glance
| Generic name | Cyclophosphamide, Methotrexate, 5 FU |
|---|---|
| Sponsor | GBG Forschungs GmbH |
| Drug class | Alkylating agent, Antimetabolite, Thymidylate synthase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Cyclophosphamide works by adding an alkyl group to the DNA of cancer cells, causing cross-linking and interfering with DNA replication. Methotrexate inhibits dihydrofolate reductase, an enzyme necessary for DNA synthesis and cell replication. 5 FU inhibits thymidylate synthase, an enzyme necessary for DNA synthesis.
Approved indications
- Breast cancer
- Lymphoma
Common side effects
- Bone marrow suppression
- Nausea and vomiting
- Mucositis
- Diarrhea
- Fatigue
Key clinical trials
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor
- Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients (PHASE3)
- 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF (PHASE3)
- ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment (PHASE3)
- Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer (PHASE3)
- Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) (PHASE3)
- Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclophosphamide, Methotrexate, 5 FU CI brief — competitive landscape report
- Cyclophosphamide, Methotrexate, 5 FU updates RSS · CI watch RSS
- GBG Forschungs GmbH portfolio CI